Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

Annals of Neurology

Volumn 76, Issue 3, 2014, Pages 325-337

  Colombo, Emanuela ^a   Di Dario, Marco ^a   Capitolo, Eleonora ^a   Chaabane, Linda ^a   Newcombe, Jia ^b   Martino, Gianvito ^a   Farina, Cinthia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FINGOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; NITRIC OXIDE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; UNCLASSIFIED DRUG; IL17RA PROTEIN, HUMAN; IL1R1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; NEUROPROTECTIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL INTERACTION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SPINAL CORD NERVE CELL; UPREGULATION; AGED; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; RAT; SPINAL CORD; SPRAGUE DAWLEY RAT;

AGED; ANIMALS; ASTROCYTES; CELLS, CULTURED; CEREBRUM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-17; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; SPINAL CORD;

EID: 84907873464     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24217     Document Type: Article

References (37)

1. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011;11:403-415.
2. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-195.
3. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117:77-93.
4. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64: 1199-1209.
5. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007;102:1151-1161.
6. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.
7. Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010;58:1465-1476.
8. Fischer I, Alliod C, Martinier N, et al. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One 2011; 6:e23905.
9. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-897.
10. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323:469-475.
11. van Doorn R, Nijland PG, Dekker N, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012;124: 397-410.
12. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009;32:638-647.
13. Colombo E, Cordiglieri C, Melli G, et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med 2012;209:521-535.
14. Colombo E, Farina C. Star trk(B): the astrocyte path to neurodegeneration. Cell Cycle 2012;11:2225-2226.
15. Cordiglieri C, Farina C. Astrocytes exert and control immune responses in the brain. Curr Immunol Rev 2010;6:150-159.
16. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007;28:138-145.
17. Brambilla R, Persaud T, Hu X, et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 2009;182:2628-2640.
18. Lebman DA, Spiegel S. Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling. J Lipid Res 2008;49:1388-1394.
19. Menon R, Di Dario M, Cordiglieri C, et al. Gender-based blood transcriptomes and interactomes in multiple sclerosis: involvement of SP1 dependent gene transcription. J Autoimmun 2012;38: J144-J155.
20. Colombo E, Romaggi S, Medico E, et al. Human neurotrophin receptor p75NTR defines differentiation-oriented skeletal muscle precursor cells: implications for muscle regeneration. J Neuropathol Exp Neurol 2011;70:133-142.
21. Melli G, Keswani SC, Fischer A, et al. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006;129(pt 5):1330-1338.
22. Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010;51:3074-3087.
23. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508.
24. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol 2004;55:46-57.
25. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-1175.
26. Ching S, Zhang H, Belevych N, et al. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci 2007;27:10476-10486.
27. Kang Z, Altuntas CZ, Gulen MF, et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010;32:414-425.
28. Okada T, Kajimoto T, Jahangeer S, Nakamura S. Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system. Cell Signal 2009;21:7-13.
29. Wu YP, Mizugishi K, Bektas M, et al. Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet 2008;17:2257-2264.
30. Deogracias R, Yazdani M, Dekkers MP, et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 2012;109:14230-14235.
31. Wu C, Leong SY, Moore CS, et al. Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J Neuroinflammation 2013;10:41.
32. Brambilla R, Hurtado A, Persaud T, et al. Transgenic inhibition of astroglial NF-kappa B leads to increased axonal sparing and sprouting following spinal cord injury. J Neurochem 2009;110: 765-778.
33. Brambilla R, Dvoriantchikova G, Barakat D, et al. Transgenic inhibition of astroglial NF-kappaB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis. J Neuroinflammation 2012;9:213.
34. Raasch J, Zeller N, van Loo G, et al. IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain 2011;134(pt 4):1184-1198.
35. Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007;8:766-775.
36. Trajkovic V, Stosic-Grujicic S, Samardzic T, et al. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. J Neuroimmunol 2001;119:183-191.
37. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011;108:751-756.